<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02488109</url>
  </required_header>
  <id_info>
    <org_study_id>P0504491</org_study_id>
    <secondary_id>1R01HD082166-01A1</secondary_id>
    <nct_id>NCT02488109</nct_id>
    <nct_alias>NCT02621229</nct_alias>
  </id_info>
  <brief_title>Study of Refeeding to Optimize iNpatient Gains</brief_title>
  <acronym>StRONG</acronym>
  <official_title>Multi-center Randomized Controlled Trial of Refeeding in Anorexia Nervosa</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of California, San Francisco</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Stanford University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>University of California, San Francisco</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to compare the efficacy, safety, and cost-effectiveness of lower&#xD;
      calorie refeeding versus higher calorie refeeding in hospitalized adolescents with anorexia&#xD;
      nervosa.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">February 2016</start_date>
  <completion_date type="Actual">June 3, 2020</completion_date>
  <primary_completion_date type="Actual">April 22, 2020</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number of Participants With Clinical Remission at Different Time Points of Assessment</measure>
    <time_frame>up to 12 months</time_frame>
    <description>Clinical remission was defined as the combination of percentage mBMI and EDE-Q score at 1, 3, 6, and 12 months. This is a dichotomous variable 1/0. If participants achieve both weight recovery (defined as =&gt;95% of median BMI for sex and age), AND psychological recovery (defined as within 1SD of community norms for EDE-Q) then they are assigned a &quot;1&quot; for achieving clinical remission. If both parameters not met then &quot;0&quot; for not remitted.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Time to Achieve Medical Stability in Hospital</measure>
    <time_frame>Inpatient hospitalization from day of admission to day of discharge, average of 10 days</time_frame>
    <description>Medical stability was adjudicated by a 6-point clinical index: (1) 24-hour heart rate of 45 beats/min or more, (2) systolic blood pressure of 90 mm Hg or more, (3) temperature of 35.6 째C or more, (4) orthostatic increase in heart rate of 35 beats/min or less, (5) orthostatic decrease in systolic blood pressure of 20 mm Hg or less, and (6) 75% or more of mBMI for age and sex. Criteria were assessed daily; for vital signs with multiple daily measures, the most deviant value was recorded (eg, lowest heart rate). Each criterion was scored as &quot;1&quot; if met, &quot;0&quot; if unmet, and missing (not scored) if not measured. Medical stability was considered restored when all measured criteria were stable for 24 hours, allowing a maximum of 2 missing values. Additional efficacy outcomes were time to restore heart rate to 45 beats/min or more (among those with bradycardia at baseline) and weight gain (change in percentage mBMI).</description>
  </secondary_outcome>
  <other_outcome>
    <measure>Cost-effectiveness Per Adolescent Recovered</measure>
    <time_frame>up to 12 months</time_frame>
    <description>defined as total cost (direct and indirect costs)</description>
  </other_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">120</enrollment>
  <condition>Anorexia Nervosa</condition>
  <arm_group>
    <arm_group_label>Higher Calorie Refeeding Protocol</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Participants in this arm will receive a higher calorie meal-based refeeding treatment plan in hospital.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Lower Calorie Refeeding Protocol</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Participants in this arm will receive a lower calorie meal-based refeeding treatment plan in hospital.</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Higher Calorie Refeeding</intervention_name>
    <arm_group_label>Higher Calorie Refeeding Protocol</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Lower Calorie Refeeding</intervention_name>
    <arm_group_label>Lower Calorie Refeeding Protocol</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  diagnosis of AN&#xD;
&#xD;
          -  atypical AN&#xD;
&#xD;
          -  no hospital admissions for the previous six months&#xD;
&#xD;
          -  meet hospitalization criteria: daytime heart rate (HR) &lt; 50 bpm or night time HR &lt; 45&#xD;
             bpm, blood pressure (BP) &lt;90/45 mmHg, temperature &lt; 35.6째 C, or symptomatic&#xD;
             orthostasis defined by increase in HR &gt; 35 bpm or decrease in systolic BP &gt; 20 mmHg or&#xD;
             decrease in diastolic BP &gt; 10 mmHg from lying to standing&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  diagnosis of bulimia nervosa [DSM-5]&#xD;
&#xD;
          -  currently in remission (as defined by weight and EDE-Q score)&#xD;
&#xD;
          -  admission for food refusal without malnutrition&#xD;
&#xD;
          -  current pregnancy&#xD;
&#xD;
          -  chronic disease (e.g. immune/endocrine disorders, pulmonary, cardiac, or renal&#xD;
             disease)&#xD;
&#xD;
          -  current suicidality or psychosis&#xD;
&#xD;
          -  &lt; 60% mBMI&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>12 Years</minimum_age>
    <maximum_age>24 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Andrea K Garber, PhD, RD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of California, San Francisco</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Stanford University Lucille Packard Children's Hospital</name>
      <address>
        <city>Palo Alto</city>
        <state>California</state>
        <zip>94304</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of California, San Francisco Benioff Children's Hospital</name>
      <address>
        <city>San Francisco</city>
        <state>California</state>
        <zip>94158</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>June 2021</verification_date>
  <study_first_submitted>June 23, 2015</study_first_submitted>
  <study_first_submitted_qc>June 30, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">July 2, 2015</study_first_posted>
  <results_first_submitted>April 21, 2021</results_first_submitted>
  <results_first_submitted_qc>June 2, 2021</results_first_submitted_qc>
  <results_first_posted type="Actual">June 24, 2021</results_first_posted>
  <last_update_submitted>June 2, 2021</last_update_submitted>
  <last_update_submitted_qc>June 2, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">June 24, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>anorexia nervosa</keyword>
  <keyword>eating disorders</keyword>
  <keyword>refeeding</keyword>
  <keyword>adolescent medicine</keyword>
  <keyword>nutritional rehabilitation</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Anorexia</mesh_term>
    <mesh_term>Anorexia Nervosa</mesh_term>
  </condition_browse>
  <provided_document_section>
    <provided_document>
      <document_type>Study Protocol and Statistical Analysis Plan</document_type>
      <document_has_protocol>Yes</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>Yes</document_has_sap>
      <document_date>July 31, 2019</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/09/NCT02488109/Prot_SAP_000.pdf</document_url>
    </provided_document>
  </provided_document_section>

  <clinical_results>

    <participant_flow>
      <recruitment_details>Patients were enrolled from February 8, 2016, to March 7, 2019 at 2 clinical sites, large tertiary care children's hospitals with eating disorder inpatient programs attended by interdisciplinary adolescent medicine care teams at the University of California San Francisco and Stanford University. Written informed consent was obtained from young adults and parents of minors, who provided written assent.</recruitment_details>
      <pre_assignment_details>Although 120 participants were randomized,116 started on the study. Of the 4 individuals who were randomized but did not receive treatment, 3 were found ineligible and 1 did not complete the consent, leaving 56 individuals in the LCR arm. Of those 56 individuals, an additional 5 individuals withdrew prior to receiving treatment, ultimately resulting in 51 participants in the LCR arm.</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>Higher Calorie Refeeding (HCR) Protocol</title>
          <description>Meal-based refeeding in hospital: starting 2000 kcal/d and increasing 200 kcal/d to goal</description>
        </group>
        <group group_id="P2">
          <title>Lower Calorie Refeeding (LCR) Protocol</title>
          <description>Meal-based refeeding in hospital: starting 1400 kcal/d and increasing 200 kcal every other day to goal</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Treatment in Hospital</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="60"/>
                <participants group_id="P2" count="56"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>Received Treatment</title>
              <participants_list>
                <participants group_id="P1" count="60"/>
                <participants group_id="P2" count="51"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>Included in mITT Analysis</title>
              <participants_list>
                <participants group_id="P1" count="60"/>
                <participants group_id="P2" count="51"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="60"/>
                <participants group_id="P2" count="51"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="5"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="5"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
        <period>
          <title>12-month Follow-Up</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="60"/>
                <participants group_id="P2" count="51"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>Included in mITT Analysis</title>
              <participants_list>
                <participants group_id="P1" count="60"/>
                <participants group_id="P2" count="51"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="56"/>
                <participants group_id="P2" count="44"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="4"/>
                <participants group_id="P2" count="7"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="4"/>
                <participants group_id="P2" count="7"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <population>Modified Intention to Treat Analysis (mITT) includes all participants who received treatment</population>
      <group_list>
        <group group_id="B1">
          <title>Higher Calorie Refeeding (HCR) Protocol</title>
          <description>Meal-based refeeding in hospital: starting 2000 kcal/d and increasing 200 kcal/d to goal</description>
        </group>
        <group group_id="B2">
          <title>Lower Calorie Refeeding (LCR) Protocol</title>
          <description>Meal-based refeeding in hospital: starting 1400 kcal/d and increasing 200 kcal every other day to goal</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="60"/>
            <count group_id="B2" value="56"/>
            <count group_id="B3" value="116"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="16.6" spread="2.5"/>
                    <measurement group_id="B2" value="16.2" spread="2.4"/>
                    <measurement group_id="B3" value="16.4" spread="2.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="53"/>
                    <measurement group_id="B2" value="52"/>
                    <measurement group_id="B3" value="105"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="7"/>
                    <measurement group_id="B2" value="4"/>
                    <measurement group_id="B3" value="11"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race/Ethnicity, Customized</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <title>Race/ethnicity</title>
              <category_list>
                <category>
                  <title>Non-Hispanic White</title>
                  <measurement_list>
                    <measurement group_id="B1" value="36"/>
                    <measurement group_id="B2" value="33"/>
                    <measurement group_id="B3" value="69"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Asian</title>
                  <measurement_list>
                    <measurement group_id="B1" value="7"/>
                    <measurement group_id="B2" value="7"/>
                    <measurement group_id="B3" value="14"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="15"/>
                    <measurement group_id="B2" value="9"/>
                    <measurement group_id="B3" value="24"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Other or &gt;1 race/ethnicity reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                    <measurement group_id="B2" value="7"/>
                    <measurement group_id="B3" value="9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="60"/>
                    <measurement group_id="B2" value="56"/>
                    <measurement group_id="B3" value="116"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Admission percentage of median body mass index (%mBMI)</title>
          <units>% of mBMI</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="83.3" spread="11.1"/>
                    <measurement group_id="B2" value="86.6" spread="12.2"/>
                    <measurement group_id="B3" value="84.6" spread="11.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Lowest 24-hr heart rate, beats/min</title>
          <units>beats per minute</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="41.5" spread="6.9"/>
                    <measurement group_id="B2" value="40.7" spread="5.9"/>
                    <measurement group_id="B3" value="41.3" spread="6.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Lowest Systolic Blood Pressure (mm Hg)</title>
          <units>mm Hg</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="94.2" spread="8.0"/>
                    <measurement group_id="B2" value="93.3" spread="8.3"/>
                    <measurement group_id="B3" value="93.7" spread="8.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Global Eating Disorder Examination Questionnaire score (mean, SD)</title>
          <description>Scores range from 1-6, with higher scores indicating greater severity. For reference, the EDE-Q global score in community studies is 3.38.</description>
          <units>Score on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="3.32" spread="1.68"/>
                    <measurement group_id="B2" value="3.45" spread="1.71"/>
                    <measurement group_id="B3" value="3.34" spread="1.70"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Atypical anorexia nervosa (No., %)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="21"/>
                    <measurement group_id="B2" value="27"/>
                    <measurement group_id="B3" value="48"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Number of Participants With Clinical Remission at Different Time Points of Assessment</title>
        <description>Clinical remission was defined as the combination of percentage mBMI and EDE-Q score at 1, 3, 6, and 12 months. This is a dichotomous variable 1/0. If participants achieve both weight recovery (defined as =&gt;95% of median BMI for sex and age), AND psychological recovery (defined as within 1SD of community norms for EDE-Q) then they are assigned a &quot;1&quot; for achieving clinical remission. If both parameters not met then &quot;0&quot; for not remitted.</description>
        <time_frame>up to 12 months</time_frame>
        <population>Clinical remission defined as the combination of %mBMI and EDE-Q score. Instead of assuming missing data at random in the generalized linear mixed-effects regression model, clinical remission was modeled as a nominal multinomial outcome (yes, no, or missing), with time (1, 3, 6, or 12 months after discharge), treatment group, and time*treatment group interaction as fixed effects. Longitudinal analysis included only participants with both %mBMI and EDE-Q scores.</population>
        <group_list>
          <group group_id="O1">
            <title>Higher Calorie Refeeding (HCR) Protocol</title>
            <description>Meal-based refeeding in hospital: starting 2000 kcal/d and increasing 200 kcal/d to goal</description>
          </group>
          <group group_id="O2">
            <title>Lower Calorie Refeeding (LCR) Protocol</title>
            <description>Meal-based refeeding in hospital: starting 1400 kcal/d and increasing 200 kcal every other day to goal</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Clinical Remission at Different Time Points of Assessment</title>
          <description>Clinical remission was defined as the combination of percentage mBMI and EDE-Q score at 1, 3, 6, and 12 months. This is a dichotomous variable 1/0. If participants achieve both weight recovery (defined as =&gt;95% of median BMI for sex and age), AND psychological recovery (defined as within 1SD of community norms for EDE-Q) then they are assigned a &quot;1&quot; for achieving clinical remission. If both parameters not met then &quot;0&quot; for not remitted.</description>
          <population>Clinical remission defined as the combination of %mBMI and EDE-Q score. Instead of assuming missing data at random in the generalized linear mixed-effects regression model, clinical remission was modeled as a nominal multinomial outcome (yes, no, or missing), with time (1, 3, 6, or 12 months after discharge), treatment group, and time*treatment group interaction as fixed effects. Longitudinal analysis included only participants with both %mBMI and EDE-Q scores.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="44"/>
                <count group_id="O2" value="34"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>1 month</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="40"/>
                    <count group_id="O2" value="32"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="12"/>
                    <measurement group_id="O2" value="8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>3 months</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="39"/>
                    <count group_id="O2" value="34"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="10"/>
                    <measurement group_id="O2" value="13"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>6 months</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="39"/>
                    <count group_id="O2" value="26"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="16"/>
                    <measurement group_id="O2" value="10"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>12 months</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="44"/>
                    <count group_id="O2" value="27"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="18"/>
                    <measurement group_id="O2" value="13"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>The study was powered to detect a difference in 12-months clinical remission rates between groups. N = 60 per arm with 85% retention would provide 80% power on a 2-sided 0.05-level test to detect a 20% difference between groups in 12-months clinical remission rates. A generalized linear mixed-effects regression model was used to compare study arms with respect to achievement and maintenance of clinical remission.</groups_desc>
            <non_inferiority_type>Other</non_inferiority_type>
            <p_value>0.42</p_value>
            <p_value_desc>Changes in rates of clinical remission by group over time in the mITT model.</p_value_desc>
            <method>Regression, Linear</method>
            <method_desc>Clinical remission was modeled as a nominal multinomial outcome (yes, no, or missing)</method_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Time to Achieve Medical Stability in Hospital</title>
        <description>Medical stability was adjudicated by a 6-point clinical index: (1) 24-hour heart rate of 45 beats/min or more, (2) systolic blood pressure of 90 mm Hg or more, (3) temperature of 35.6 째C or more, (4) orthostatic increase in heart rate of 35 beats/min or less, (5) orthostatic decrease in systolic blood pressure of 20 mm Hg or less, and (6) 75% or more of mBMI for age and sex. Criteria were assessed daily; for vital signs with multiple daily measures, the most deviant value was recorded (eg, lowest heart rate). Each criterion was scored as &quot;1&quot; if met, &quot;0&quot; if unmet, and missing (not scored) if not measured. Medical stability was considered restored when all measured criteria were stable for 24 hours, allowing a maximum of 2 missing values. Additional efficacy outcomes were time to restore heart rate to 45 beats/min or more (among those with bradycardia at baseline) and weight gain (change in percentage mBMI).</description>
        <time_frame>Inpatient hospitalization from day of admission to day of discharge, average of 10 days</time_frame>
        <population>Modified intention to treat analysis (mITT) included all participants who received at least one day of treatment</population>
        <group_list>
          <group group_id="O1">
            <title>Higher Calorie Refeeding (HCR)</title>
            <description>Meal-based refeeding in hospital: starting 2000 kcal/d and increasing 200 kcal/d to goal</description>
          </group>
          <group group_id="O2">
            <title>Lower Calorie Refeeding (LCR)</title>
            <description>Meal-based refeeding in hospital: starting 1400 kcal/d and increasing 200 kcal every other day to goal</description>
          </group>
        </group_list>
        <measure>
          <title>Time to Achieve Medical Stability in Hospital</title>
          <description>Medical stability was adjudicated by a 6-point clinical index: (1) 24-hour heart rate of 45 beats/min or more, (2) systolic blood pressure of 90 mm Hg or more, (3) temperature of 35.6 째C or more, (4) orthostatic increase in heart rate of 35 beats/min or less, (5) orthostatic decrease in systolic blood pressure of 20 mm Hg or less, and (6) 75% or more of mBMI for age and sex. Criteria were assessed daily; for vital signs with multiple daily measures, the most deviant value was recorded (eg, lowest heart rate). Each criterion was scored as &quot;1&quot; if met, &quot;0&quot; if unmet, and missing (not scored) if not measured. Medical stability was considered restored when all measured criteria were stable for 24 hours, allowing a maximum of 2 missing values. Additional efficacy outcomes were time to restore heart rate to 45 beats/min or more (among those with bradycardia at baseline) and weight gain (change in percentage mBMI).</description>
          <population>Modified intention to treat analysis (mITT) included all participants who received at least one day of treatment</population>
          <units>Days</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="60"/>
                <count group_id="O2" value="51"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7.0" spread="7.0"/>
                    <measurement group_id="O2" value="10.0" spread="8.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>This trial was powered at 0.80 to detect a 12% to 20% difference in restored medical stability at 0.05 type I error and correlation between time points from 0.1 to 1.</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.01</p_value>
            <p_value_desc>Survival analysis of time to medical stability by log-rank test, which does not assume proportional hazards. Those who did not reach medical stability before hospital discharge were censored; analyses accounted for the site effect by stratification.</p_value_desc>
            <method>Survival analysis with log rank test</method>
            <method_desc>Compared time to achieve medical stability by arm; participants who did not meet stability criteria by hospital discharge were right-censored</method_desc>
            <param_type>Hazard Ratio (HR)</param_type>
            <param_value>1.67</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>1.10</ci_lower_limit>
            <ci_upper_limit>2.53</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Other Pre-specified</type>
        <title>Cost-effectiveness Per Adolescent Recovered</title>
        <description>defined as total cost (direct and indirect costs)</description>
        <time_frame>up to 12 months</time_frame>
        <population>The analysis was a modified intent-to-treat (mITT) approach including all randomized participants who received treatment for at least one day. A total of 9 participants were excluded: 3 were found to be ineligible after randomization and 6 withdrew prior to receiving treatment.</population>
        <group_list>
          <group group_id="O1">
            <title>Higher Calorie Refeeding (HCR) Protocol</title>
            <description>Meal-based refeeding in hospital: starting 2000 kcal/d and increasing 200 kcal/d to goal</description>
          </group>
          <group group_id="O2">
            <title>Lower Calorie Refeeding (LCR) Protocol</title>
            <description>Meal-based refeeding in hospital: starting 1400 kcal/d and increasing 200 kcal every other day to goal</description>
          </group>
        </group_list>
        <measure>
          <title>Cost-effectiveness Per Adolescent Recovered</title>
          <description>defined as total cost (direct and indirect costs)</description>
          <population>The analysis was a modified intent-to-treat (mITT) approach including all randomized participants who received treatment for at least one day. A total of 9 participants were excluded: 3 were found to be ineligible after randomization and 6 withdrew prior to receiving treatment.</population>
          <units>USD</units>
          <param>Median</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="60"/>
                <count group_id="O2" value="51"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="38,112" spread="26,043"/>
                    <measurement group_id="O2" value="57,168" spread="30,486"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Cost outcomes of group differences and 95% confidence intervals were estimated.</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.002</p_value>
            <method>Wilcoxon (Mann-Whitney)</method>
            <param_type>Median Difference (Net)</param_type>
            <param_value>19,056</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>9,293</ci_lower_limit>
            <ci_upper_limit>28,819</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>Participants were monitored for adverse events on an ongoing basis during the treatment period, which was during hospitalization from day of admission to day of discharge (an average of 10 days). After the treatment effect window was completed on discharge from the hospital, adverse events were not considered to be related to study treatment.</time_frame>
      <group_list>
        <group group_id="E1">
          <title>Higher Calorie Refeeding (HCR)</title>
          <description>Meal-based refeeding in hospital: starting 2000 kcal/d and increasing 200 kcal/d to goal</description>
        </group>
        <group group_id="E2">
          <title>Lower Calorie Refeeding (LCR)</title>
          <description>Meal-based refeeding in hospital: starting 1400 kcal/d and increasing 200 kcal every other day to goal. Of the 56 participants originally randomized to this treatment, 5 never received treatment and were therefore excluded from mITT analyses.</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>CTCAE (4.0)</default_vocab>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="60"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="51"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="14" subjects_at_risk="60"/>
                <counts group_id="E2" subjects_affected="10" subjects_at_risk="51"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Hypophosphatemia</sub_title>
                <description>&lt;2.5 mg/dL</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="60"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="51"/>
              </event>
              <event>
                <sub_title>Orthostatic increase in heart rate</sub_title>
                <description>An increase in heart rate from lying (for 5 min) to standing (for 2 min) was categorized as severe in this patient population if it reached a threshold of a change of &gt;75 bpm</description>
                <counts group_id="E1" events="20" subjects_affected="4" subjects_at_risk="60"/>
                <counts group_id="E2" events="16" subjects_affected="4" subjects_at_risk="51"/>
              </event>
              <event>
                <sub_title>Severe Bradycardia</sub_title>
                <description>&lt;30 bpm</description>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="60"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="51"/>
              </event>
              <event>
                <sub_title>Severe Hypotension</sub_title>
                <description>&lt;80/40</description>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="60"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="51"/>
              </event>
              <event>
                <sub_title>Other unrelated SAEs during follow-up period</sub_title>
                <description>e.g. elevated liver enzymes, sialolithiasis, gallstone pancreatitis, renal calculi, tonic clonic seizure</description>
                <counts group_id="E1" events="6" subjects_affected="6" subjects_at_risk="60"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="51"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Psychiatric SAE, e.g. suicide attempt</sub_title>
                <description>All of these psychiatric events occurred during the follow-up period, after patients were no longer in our care</description>
                <counts group_id="E1" events="4" subjects_affected="3" subjects_at_risk="60"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="51"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <default_vocab>CTCAE (4.0)</default_vocab>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="14" subjects_at_risk="60"/>
                <counts group_id="E2" subjects_affected="21" subjects_at_risk="51"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Hypokalemia (mild)</sub_title>
                <description>3.1 - 3.4 mmol/L</description>
                <counts group_id="E1" events="4" subjects_affected="3" subjects_at_risk="60"/>
                <counts group_id="E2" events="5" subjects_affected="5" subjects_at_risk="51"/>
              </event>
              <event>
                <sub_title>Hypomagnesemia (mild)</sub_title>
                <description>1.3 - 1.7 mg/dL</description>
                <counts group_id="E1" events="10" subjects_affected="7" subjects_at_risk="60"/>
                <counts group_id="E2" events="16" subjects_affected="14" subjects_at_risk="51"/>
              </event>
              <event>
                <sub_title>Hypophosphatemia (moderate)</sub_title>
                <description>Moderate: 2.5 - 2.9 mg/dL</description>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="60"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="51"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>All Principal Investigators ARE employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Andrea Garber, PhD, RD</name_or_title>
      <organization>University of California, San Francisco, Department of Pediatrics</organization>
      <phone>415-514-2180</phone>
      <email>andrea.garber@ucsf.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

